Table 1.

SCCHN risk associated with CYP1B1 V432L, CYP2E1 G1532C, and NQO1 P187S polymorphisms

GenotypeCase patients (n = 724)
Control subjects (n = 1,226)
Crude OR (95% CI)Adjusted OR (95% CI)*
No. (%)No. (%)
CYP1B1 V432L
    Val/Val238 (32.9)365 (29.8)1.001.00
    Val/Leu342 (47.2)605 (49.3)0.87 (0.70-1.07)0.86 (0.70-1.07)
    Leu/Leu144 (19.9)256 (20.9)0.86 (0.66-1.12)0.89 (0.68-1.16)
    Val/Leu + Leu/Leu486 (67.1)861 (70.2)0.87 (0.71-1.06)0.87 (0.72-1.06)
    Leu allele0.4350.456
CYP2E1 G1532C
    GG684 (94.5)1137 (92.7)1.001.00
    CG37 (5.1)86 (7.03)0.72 (0.48-1.06)0.73 (0.49-1.10)
    CC3 (0.4)3 (0.23)1.66 (0.34-8.26)1.97 (0.39-9.86)
    CG + CC40 (5.5)89 (7.23)0.75 (0.51-1.10)0.77 (0.52-1.13)
    C allele0.0300.038
NQO1 Pro187Ser
    Pro/Pro484 (66.8)805 (65.7)1.001.00
    Ser/Pro209 (28.9)388 (31.6)0.89 (0.73-1.10)0.89 (0.73-1.09)
    Ser/Ser31 (4.3)33 (2.7)1.56 (0.95-2.58)1.56 (0.94-2.59)
    Ser/Pro + Ser/Ser240 (33.2)421 (34.3)0.95 (0.78-1.15)0.94 (0.78-1.15)
    Ser allele0.1870.185
  • * Adjusted for age, sex, smoking status, and alcohol use in a logistic regression model.

  • Genotype distributions: χ2 = 3.19, P = 0.203, CYP2E1; χ2 = 4.75, P = 0.093, NQO1; and χ2 = 2.05, P = 0.359, CYP1B1, respectively. Allele frequency: χ2 = 1.83, P = 0.176, CYP2E1; χ2 = 0.02, P = 0.877, NQO1; and χ2 = 1.60, P = 0.205, CYP1B, respectively. The observed genotype frequency in the control subjects was in agreement with Hardy-Weinberg equilibrium (p2 + 2pq + q2 = 1): χ2 = 1.02, P = 0.314, CYP2E1; χ2 = 2.92, P = 0.087, NQO1; and χ2 = 0.03, P = 0.856, CYP1B, respectively.